Results of MAIC study comparing pirtobrutinib ... - CLL Support

CLL Support

23,335 members40,040 posts

Results of MAIC study comparing pirtobrutinib vs venetoclax in CLL patients previously treated with a covalent BTK inhibitor

7 Replies

You need to be a member of this community to see this post.

Read more about...
7 Replies

You need to be a member of this community to see hidden responses.

Not what you're looking for?

You may also like...

EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor

https://cllsociety.org/2022/08/eha-2022-outcomes-following-treatment-with-a-covalent-btk-and-bcl2-in

YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success

I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
AussieNeil profile image
Partner

Good News! BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

3rd April 2020 Blood Key points to note: BTK inhibitor therapy achieves durable disease...
Jm954 profile image
Administrator

Encouraging results from venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

We've heard that re-treatment with venetoclax is possible. Per the attached image, here's some...
AussieNeil profile image
Partner

BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies

Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
Jm954 profile image
Administrator